Josh Plotnik serves as a Principal Research Scientist I at AbbVie, where he plays a pivotal role in Oncology Discovery Research. With a robust background in genetics and multi-omic platforms, Josh specializes in new target identification and validation, focusing on uncovering specific vulnerabilities that can...
Josh Plotnik serves as a Principal Research Scientist I at AbbVie, where he plays a pivotal role in Oncology Discovery Research. With a robust background in genetics and multi-omic platforms, Josh specializes in new target identification and validation, focusing on uncovering specific vulnerabilities that can be exploited for targeted therapies. His expertise in advanced techniques such as CRISPR/Cas9 and RNA sequencing allows him to lead innovative cross-functional drug discovery efforts, bridging the gap between basic research and clinical application.
At AbbVie, Josh is currently spearheading several key projects aimed at developing novel oncological therapies. His work involves the integration of diverse biological data sets to elucidate the complex mechanisms of cancer biology, enabling the identification of promising therapeutic targets. By utilizing cutting-edge technologies like lentivirus for gene delivery and real-time polymerase chain reaction (qPCR) for quantifying gene expression, he ensures that his research is both rigorous and impactful.
Josh's proficiency in protein purification and fluorescence microscopy further enhances his ability to characterize potential drug candidates at a molecular level. His collaborative approach fosters synergy among multidisciplinary teams, driving forward the mission to translate scientific discoveries into effective treatments for patients. As a thought leader in the field, Josh is committed to advancing the frontiers of oncology research, making significant contributions to the development of next-generation therapies that hold the promise of improving patient outcomes.
